A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Saved in:
| Title: | A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. |
|---|---|
| Authors: | Jazieh K; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Molina J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Allred J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Yin J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Reid J; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Goetz M; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Lim VS; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Kaufmann SH; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Adjei A; Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. adjei.alex@mayo.edu. |
| Source: | Investigational new drugs [Invest New Drugs] 2019 Apr; Vol. 37 (2), pp. 307-314. Date of Electronic Publication: 2018 Aug 31. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
